June 13, 2024
Plasma Protease C1-Inhibitor Treatment Market

Plasma Protease C1-inhibitor Treatment Market is Poised to Garner High Revenues Through Technological Advancements in Plasma Fractionation

C1-inhibitor is a serine protease inhibitor that regulates the activated first component of complement and coagulation cascades. Its deficiency or dysfunction leads to increased vascular permeability and episodes of swelling commonly observed in HAE patients. The emergence of novel treatments offering enhanced potency, extended half-life, and convenient delivery methods has bolstered the demand for C1-inhibitor therapy. Rising HAE prevalence coupled with growing patient awareness is adding to the revenue potential of the market.

The Global Plasma Protease C1-inhibitor Treatment Market is estimated to be valued at US$ 6257.99 Bn in 2024 and is expected to exhibit a CAGR of 6.7% over the forecast period 2024 to 2031.

Key Takeaways
Key players operating in the plasma protease C1-inhibitor treatment market are R&D. Koninklijke Philips N.V., Panasonic Corporation, and Procter & Gamble.

The market provides ample opportunities for companies offering subcutaneous and self-administrable C1-inhibitor therapies with enhanced stability and reduced frequency of dosing. Rapid and self-administrable treatment options allow patients to intervene early in case of HAE attacks.

Technological advancements in plasma fractionation techniques aid the development of highly purified Plasma Protease C1-Inhibitor Treatment Market Size concentrates with extended shelf life and potency. Recombinant C1-inhibitor therapies also eliminate the risk of blood-borne infections and issues related to plasma supply.

Market Drivers
The increasing prevalence of hereditary angioedema globally is a prime factor driving the demand for C1-inhibitor treatments. As per estimates, HAE affects 1 in 10,000 to 1 in 50,000 people worldwide. Growing awareness regarding treatment options also encourages patients to opt for C1-inhibitor therapy to control symptoms and improve quality of life. Moreover, targeted approaches by companies to educate patients regarding prophylactic therapy adoption favors market growth.

Current Challenges in Plasma Protease C1-inhibitor Treatment Market
The plasma protease C1-inhibitor treatment market is facing various challenges currently. One major challenge is lack of availability of plasma derived C1-inhibitor treatment products in certain regions. This results in inadequate treatment options and delays in receiving therapy for patients suffering from hereditary angioedema. High production costs involved in manufacturing plasma derived therapies is another challenge. Developing recombinant therapies which are more cost effective can help address this challenge. Other challenges include need for frequent administration of plasma derived products and associated discomfort in patients. Real world adherence to therapy protocols also needs improvement.

SWOT Analysis
Strength: Plasma derived C1-inhibitor concentrates are well established with proven efficacy and safety.

Weakness: High production costs and limited supply availability.

Opportunity: Potential for development of alternative therapies like recombinant C1-inhibitors with improved profile.

Threats: Intense competition from new drug launches and biosimilars in future.

Geographical Regions
Currently, the market in North America accounts for the largest share in terms of value due to established patient diagnosis and treatment landscape. However, Asia Pacific region is estimated to grow at the fastest pace during the forecast period owing to rising healthcare spending, increasing awareness and improving access to therapies.

The United States holds the highest market share currently in the plasma protease C1-inhibitor treatment market attributed to strong diagnosis rates, availability of reimbursement and wide acceptance of current standard of care plasma derived therapies. Several supporting patient programs and nonprofit organizations also help boost treatment rates in the country.

India and China represent major growth opportunities for players. This is due to the huge patient population, increasing healthcare expenditures and focus on expanding emergency care infrastructure to manage hereditary angioedema attacks. The Asia Pacific region excluding Japan and China is also poised to witness high demand for C1-inhibitor therapies with economic development across various countries.

*Note:
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it